FTC creates an internal Healthcare Task Force
The FTC has created an internal Healthcare Task Force that puts misleading telehealth and weight-loss marketing on its enforcement radar, a move that could affect how GLP-1 programs advertise and sell to patients.
The Federal Trade Commission is standing up a new internal Healthcare Task Force, and weight-loss and telehealth marketing are among the areas it plans to watch closely. Chairman Andrew N. Ferguson issued a memorandum on March 20 directing the agency to create the task force, describing healthcare as a top enforcement and policy priority [1].
The memo frames the effort around a basic tension: healthcare spending makes up roughly 18% of U.S. gross domestic product, yet many patients still struggle to get affordable care [1]. Ferguson's memo ties that gap to consolidation and other conduct across healthcare markets, and to regulations he says can weaken incentives to lower costs or raise quality, with a specific nod to effects on rural communities, seniors, and veterans [1].
The task force will pull together several parts of the FTC, including the Bureau of Competition, the Bureau of Consumer Protection, the Bureau of Economics, the Office of Policy Planning, and the Office of Technology, so that information from one investigation can more easily feed into others [1]. It is also meant to expand collaboration with other federal agencies, including the Department of Health and Human Services and the Department of Justice, which could mean more coordinated federal activity on healthcare marketing and pricing issues [1].
Among its stated priorities, the memo lists continued scrutiny of consumer protection matters in healthcare marketing, specifically citing past actions over deceptive health plan marketing, misleading telehealth and weight-loss programs, and products promoted with unsupported claims for serious conditions [1]. The memo signals that any company marketing health products or services should expect ongoing attention to how it substantiates claims, discloses information, uses endorsements, and steers consumers toward particular products [1]. Pharmacy benefit managers, drug pricing, and transparency are also called out as focus areas, with attention to rebates, formulary design, and steering practices [1].
Why it matters for patients
Many people looking into GLP-1 medications like Ozempic, Wegovy, Zepbound, or compounded semaglutide first encounter these products through telehealth platforms or online weight-loss programs. The task force's stated interest in
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.